Key result
HUFA index accurately differentiates NASH from simple steatosis with an AUROC of 0.94.
Why the study?
Noninvasive, sensitive diagnostic tests are needed to differentiate simple steatosis from NASH in patients with NAFLD to reduce reliance on liver biopsy.
Does the HUFA index accurately differentiate NASH from simple steatosis in patients with NAFLD?
Cross-Sectional (n=111)
Does the HUFA index accurately differentiate NASH from simple steatosis in patients with NAFLD?
Effect estimate: AUROC 0.94
The HUFA index, comprising four routine blood parameters, offers a highly specific, non-invasive method to identify NASH in patients with NAFLD, potentially reducing the need for liver biopsy.
Non-invasive NASH tests show promise in cross-sectional data; leaves open accuracy and clinical adoption pending prospective validation.
Background and objectives: Data suggests that nearly 30% of the general population have steatosis and up to 5% of this population develops nonalcoholic steatohepatitis (NASH). Liver biopsy is still considered to be the gold standard for the diagnosis of NASH. Great effort is being made toward the identification of sensitive diagnostic tests that do not involve invasive procedures to address a common concern in patients with the nonalcoholic fatty liver disease—whether they have NASH or simple steatosis. We aimed to investigate the independent predictors and develop a non-invasive, easy-to-perform, low-cost set of parameters that may be used in clinical practice to differentiate simple steatosis from NASH. Methods: А cross-sectional study of nonalcoholic fatty liver disease (NAFLD) patients divided into two groups: group I—simple steatosis (SS) and group II—biopsy-proven NASH. Strict inclusion criteria and stepwise analysis allowed the evaluation of a vast number of measured/estimated parameters. Results: One hundred and eleven patients were included—82 with simple steatosis and 29 with biopsy-proven NASH. The probability of NASH was the highest when homeostatic model assessment of insulin resistance (HOMA-IR) was above 2.5, uric acid above 380 µmol/L, ferritin above 100 µg/L and ALT above 45 U/L. An acronym of using first letters was created and named the HUFA index. This combined model resulted in an area under the receiver operator characteristic curve (AUROC) of 0.94, provided sensitivity, specificity, positive predictive value and a negative predictive value for NASH of 70.3%, 95.1%, 83.1% and 90.0%, respectively. Conclusion: We suggest a simple non-invasive predictive index HUFA that encompasses four easily available parameters (HOMA-IR, uric acid, ferritin and ALT) to identify patients with NASH, which may reduce the need for a liver biopsy on a routine basis in patients with NAFLD.
No takes yet. Share an insight, caveat, or question.
Ćulafić et al. (2019) conducted a cross-sectional in Nonalcoholic fatty liver disease (NAFLD) (n=111). HUFA index (HOMA-IR, uric acid, ferritin, and ALT) vs. Liver biopsy (gold standard) was evaluated on Identification of biopsy-proven NASH (AUROC 0.94). The HUFA index accurately differentiated NASH from simple steatosis with an AUROC of 0.94, providing 70.3% sensitivity and 95.1% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: